类器官模型在转化胰腺癌研究中的应用。
Organoid models for translational pancreatic cancer research.
机构信息
Cold Spring Harbor Laboratory, NCI-designated Cancer Center, 1 Bungtown Rd., Cold Spring Harbor, NY 11724, United States; University of California San Diego, Department of Surgery, NCI-designated Comprehensive Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093-0987, United States.
Cold Spring Harbor Laboratory, NCI-designated Cancer Center, 1 Bungtown Rd., Cold Spring Harbor, NY 11724, United States.
出版信息
Curr Opin Genet Dev. 2019 Feb;54:7-11. doi: 10.1016/j.gde.2019.02.003. Epub 2019 Mar 4.
Abstract
Despite recent advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) still retains the worst survival rate of common malignancies. Late diagnosis and lack of curative therapeutic options are the most pressing clinical problems for this disease. Therefore, there is a need for patient models and biomarkers that can be applied in the clinic to identify the most effective therapy for a patient. Pancreatic ductal organoids are ex-vivo models of PDAC that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. Organoids models have been applied to pancreatic cancer research and offer a promising platform for precision medicine approaches.
摘要
尽管癌症治疗在最近取得了进展，但胰腺导管腺癌（PDAC）的存活率仍然是常见恶性肿瘤中最差的。晚期诊断和缺乏有效的治疗选择是该疾病最紧迫的临床问题。因此，需要能够应用于临床的患者模型和生物标志物，以确定对患者最有效的治疗方法。胰腺导管类器官是 PDAC 的体外模型，可以从小活检中建立，从而能够研究局部、晚期和转移性患者。类器官模型已应用于胰腺癌研究，并为精准医学方法提供了有前途的平台。
相似文献
1
Organoid models for translational pancreatic cancer research.类器官模型在转化胰腺癌研究中的应用。
Curr Opin Genet Dev. 2019 Feb;54:7-11. doi: 10.1016/j.gde.2019.02.003. Epub 2019 Mar 4.
2
Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.患者来源类器官药物代谢分型指导胰腺癌精准医疗。
Clin Cancer Res. 2022 Aug 2;28(15):3176-3178. doi: 10.1158/1078-0432.CCR-22-1083.
3
Organoid models of human and mouse ductal pancreatic cancer.人类和小鼠胰腺导管癌的类器官模型
Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.
4
Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.患者来源的胰腺肿瘤类器官鉴定对溶瘤腺病毒的治疗反应。
EBioMedicine. 2020 Jun;56:102786. doi: 10.1016/j.ebiom.2020.102786. Epub 2020 May 24.
5
State-matched organoid models to fight pancreatic cancer.基于器官芯片的个体化模型对抗胰腺癌。
Trends Cancer. 2022 Jun;8(6):445-447. doi: 10.1016/j.trecan.2022.03.003. Epub 2022 Mar 31.
6
[Organoids from pancreatic ductal adenocarcinoma].[来自胰腺导管腺癌的类器官]
Med Sci (Paris). 2020 Jan;36(1):57-62. doi: 10.1051/medsci/2019259. Epub 2020 Feb 4.
7
Pancreatic cancer subtypes: a roadmap for precision medicine.胰腺癌亚型：精准医学的路线图。
Ann Med. 2018 Jun;50(4):277-287. doi: 10.1080/07853890.2018.1453168. Epub 2018 Mar 22.
8
Update on the management of pancreatic cancer: surgery is not enough.胰腺癌管理的最新进展：手术并不够。
World J Gastroenterol. 2015 Mar 21;21(11):3157-65. doi: 10.3748/wjg.v21.i11.3157.
9
Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.匹配的导管胰腺腺癌类器官和血浆样本的共享细胞外囊泡 miRNA 图谱显示了类器官技术的威力。
Cell Mol Life Sci. 2021 Mar;78(6):3005-3020. doi: 10.1007/s00018-020-03703-8. Epub 2020 Nov 25.
10
Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.建立胰腺导管腺癌类器官模型并筛选个体化治疗策略。
Animal Model Exp Med. 2023 Oct;6(5):409-418. doi: 10.1002/ame2.12352. Epub 2023 Oct 27.
引用本文的文献
1
CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook.CRISPR/Cas技术在胰腺癌研究与治疗中的应用：最新进展与未来展望
Discov Oncol. 2025 Aug 11;16(1):1530. doi: 10.1007/s12672-025-03383-5.
2
Harnessing Organoid Platforms for Nanoparticle Drug Development.利用类器官平台进行纳米颗粒药物开发。
Drug Des Devel Ther. 2025 Jul 18;19:6125-6143. doi: 10.2147/DDDT.S530999. eCollection 2025.
3
Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment.结合胰腺癌患者来源肿瘤细胞（PDO）的分子特征与治疗分析可预测临床反应并指导胰腺癌的个性化治疗。
J Exp Clin Cancer Res. 2025 Feb 26;44(1):72. doi: 10.1186/s13046-025-03332-8.
4
Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology.推进胰腺癌研究与治疗：类器官技术的变革性作用。
Exp Mol Med. 2025 Feb;57(1):50-58. doi: 10.1038/s12276-024-01378-w. Epub 2025 Jan 16.
5
Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells.人类胰腺癌单细胞图谱揭示了CXCL10+成纤维细胞与基底亚型肿瘤细胞之间的关联。
Clin Cancer Res. 2025 Feb 17;31(4):756-772. doi: 10.1158/1078-0432.CCR-24-2183.
6
Differential Effects of Confinement on the Dynamics of Normal and Tumor-Derived Pancreatic Ductal Organoids.限制对正常和肿瘤来源的胰腺导管类器官动力学的不同影响。
ACS Appl Bio Mater. 2024 Dec 16;7(12):8489-8502. doi: 10.1021/acsabm.4c01301. Epub 2024 Nov 22.
7
Strategic insights into the cultivation of pancreatic cancer organoids from endoscopic ultrasonography-guided biopsy tissue.从内镜超声引导下活检组织中培养胰腺癌类器官的策略见解。
World J Gastroenterol. 2024 Nov 14;30(42):4532-4543. doi: 10.3748/wjg.v30.i42.4532.
8
A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention.一种可靶向的分泌型神经蛋白驱动胰腺癌转移定植和HIF1α核内滞留。
Cancer Discov. 2024 Dec 2;14(12):2489-2508. doi: 10.1158/2159-8290.CD-23-1323.
9
Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.使用 KRAS 和 MEK 抑制剂联合放疗对胰腺癌进行致癌性 RAS 信号的三重阻断。
Int J Mol Sci. 2024 Jun 6;25(11):6249. doi: 10.3390/ijms25116249.
10
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.细胞外基质微环境和肿瘤微环境增强 KRAS 抑制剂在胰腺癌中的疗效。
Cancer Res. 2024 Apr 1;84(7):1115-1132. doi: 10.1158/0008-5472.CAN-23-2504.
本文引用的文献
1
Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer.全基因组定义了胰腺癌匹配的原发肿瘤、异种移植肿瘤和类器官模型的一致性。
PLoS Comput Biol. 2019 Jan 10;15(1):e1006596. doi: 10.1371/journal.pcbi.1006596. eCollection 2019 Jan.
2
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
3
TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.TP63 介导的增强子重编程驱动胰腺导管腺癌的鳞状亚型。
Cell Rep. 2018 Nov 13;25(7):1741-1755.e7. doi: 10.1016/j.celrep.2018.10.051.
4
Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens.从切除的肿瘤标本中生成和培养人胰腺导管腺癌类器官
Methods Mol Biol. 2019;1882:97-115. doi: 10.1007/978-1-4939-8879-2_9.
5
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.IL1 诱导的 JAK/STAT 信号被 TGFβ拮抗，从而塑造胰腺导管腺癌中 CAF 的异质性。
Cancer Discov. 2019 Feb;9(2):282-301. doi: 10.1158/2159-8290.CD-18-0710. Epub 2018 Oct 26.
6
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.一个全面的人类胃癌类器官生物库捕获了肿瘤亚型异质性，并能够进行治疗筛选。
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.
7
Neurogenin3 phosphorylation controls reprogramming efficiency of pancreatic ductal organoids into endocrine cells.神经母细胞生成素 3 磷酸化控制胰腺导管类器官重编程为内分泌细胞的效率。
Sci Rep. 2018 Oct 18;8(1):15374. doi: 10.1038/s41598-018-33838-5.
8
Initiation, Expansion, and Cryopreservation of Human Primary Tissue-Derived Normal and Diseased Organoids in Embedded Three-Dimensional Culture.人原代组织来源的正常和病变类器官在嵌入式三维培养中的起始、扩增及冷冻保存
Curr Protoc Cell Biol. 2019 Mar;82(1):e66. doi: 10.1002/cpcb.66. Epub 2018 Sep 28.
9
Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.人类类器官与原发性胰腺腺癌肿瘤在结构和遗传特征上具有相似性。
Mol Cancer Res. 2019 Jan;17(1):70-83. doi: 10.1158/1541-7786.MCR-18-0531. Epub 2018 Aug 31.
10
Genetic and transcriptional evolution alters cancer cell line drug response.遗传和转录进化改变癌细胞系的药物反应。
Nature. 2018 Aug;560(7718):325-330. doi: 10.1038/s41586-018-0409-3. Epub 2018 Aug 8.
Zotero 插件